Similar articles

Abstract: Objective: To investigate the effect of activated protein C (APC) on inflammatory responses in human umbilical vein endothelial cells (HUVEC) stimulated with lipopolysaccharide (LPS). Methods: The second passage of collagenase digested HUVEC was divided into the following groups: serum free medium control group (SFM control), phosphate buffer solution control group (PBS control), LPS group with final concentration of 1 μg/ml (LPS group), APC group with final concentration of 7 μg/ml, Pre-APC group (APC pretreatment for 30 min prior to LPS challenge), and Post-APC group (APC administration 30 min after LPS challenge). Supernatant was harvested at 0, 4, 8, 12 and 24 h after LPS challenge. interleukin-6 (IL-6) and interleukin-8 (IL-8) levels were analyzed with ELISA. Cells were harvested at 24 h after LPS challenge, and total RNA was extracted. Messenger RNA levels for IL-6 and IL-8 were semi-quantitatively determined by RT-PCR. Results: Compared with control group, IL-6 and IL-8 levels steadily increased 4 to 24 h after LPS stimulation. APC treatment could increase LPS-induced IL-6 and IL-8 production. The mRNA levels of IL-6 and IL-8 exhibited a similar change. Conclusion: APC can further increase the level of IL-6 and IL-8 induced by LPS. The effect of these elevated cytokines is still under investigation.

[1] Abraham, E., Laterre, P.F., Garg, R., 2005. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N. Engl. J. Med., 353(13):1332-1341.

[2] Aderka, D., Le, J., Vilcek, J., 1989. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J. Immunol., 143:3517-3523.

[3] Bernard, G.R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut, J.F., Lopez-Rodriguez, A., Steingrub, J.S., Garber, G.E., Helterbrand, J.D., Ely, E.W., et al., 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med., 344(10):699-709.

[4] Czeslick, E.G., Nestler, F., Andreas, S., Struppert, A., Sablotzki, A., 2005. Drotrecogin alfa (activated) does not Affect intracellular production of interleukin-6 and tumor necrosis factor-α in endotoxin-stimulated human monocytes. Anesth. Analg., 101:1805-1808.

[5] Esmon, C.T., 2000. Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood, 95:1113-1116.

[6] Grey, S.T., Csizmadia, V., Hancock, W.W., 1998. Differential effect of tumor necrosis factor-α on thrombomodulin gene expression by human monocytoid (THP-1) cells versus endothelial cells. Int. J. Hematology, 67:53-62.

[7] Hechtman, D.H., Cybulsky, M.I., Fuchs, H.J., Baker, J.B., Gimbrone, M.A.Jr, 1991. Intravascular IL-8 inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. J. Immunol., 147:883-892.

[8] Hooper, W.C., Phillips, D.J., Renshaw, M.A., Evatt, B.L., Benson, J.M., 1998. The up-regulation of IL-6 and IL-8 in human endothelial cells by activated protein C. J. Immunol., 161:2567-2573.

[9] Jaffe, E.A., Nachman, R.L., Becker, C.G., Minick, C.R., 1973. Culture of human endothelial cells derived from umbilical veins. J. Clin. Invest., 52:2745-2756.

[10] Joyce, D.E., Gelbert, L., Ciaccia, A., DeHoff, B., Grinnell, B.W., 2001. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem., 276(14):11199-11203.

[11] Lawson, J.H., Kalafatis, M., Stram, S., Mann, K.G., 1994. A model for the tissue factor pathway to thrombin. J. Bio. Chem., 269:23357-23366.

[12] Opal, S.M., 2000. Physiogenetic and functional relationships between coagulation and the innate immune response. Crit. Care Med., 28:s77-s80.

[13] Smith, W.B., Gamble, J.R., Lewis, C., Vadas, M.A., 1993. Chemotactic desensitization of neutrophils demonstrated interleukin-8 (IL-8)-dependent and IL-8-independent mechanisms of transmigration through cytokine-activated endothelium. Immunology, 78:491-497.

[14] Souter, P.J., Thomas, S., Hubbard, A., Poole, S., Romisch, J., Gray, E., 2001. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit. Care Med., 29:134-139.

[15] Taylor, F.B., Chang, A., Esmon, C.T., D'Angelo, A., Vigano-D'Angelo, S., Blick, K.E., 1987. Protein C prevents the coagulation and lethal effects of Escherichia coli infusion in the baboon. J. Clin. Invest., 79:918-925.

[16] Taylor, F.B., Chang, A.C., Peer, G.T., Mather, T., Blick, K., Catlett, R., Lockhart, M.S., Esmon, C.T., 1991. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood, 78:364-368.

[17] Tilg, H., Trehu, E., Atkins, M., Dinarello, C.A., Mier, J.W., 1994. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood, 83:113-118.

[18] Warren, B.L., Eid, A., Singer, P., Pillay, S.S., Carl, P., Novak, I., Chalupa, P., Atherstone, A., Penzes, I., Kubler, A., et al., 2001. High-dose antithrombin III in severe sepsis a randomized controlled trial. JAMA, 286(15):1869-1878.

[19] White, B., Schmidt, M., Murphy, C., Livingstone, W., O'Toole, D., Lawler, M., O'Neill, L., Kelleher, D., Schwarz, H.P., Smith, O.P., 2000. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor κB (NF-κB) and tumor necrosis factor α (TNF-α) production in the THP-1 monocytic cell line. Br. J. Haematol., 110(1):130-134.

[20] Wiedermann, C.J., Kaneider, N.C., 2005. A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis. BMC Emergency Medicine, 5(1):7.

[21] Xing, Z., Gauldie, J., Cox, G., Baumann, H., Jordana, M., Lei, X.F., Achong, M.K., 1998. IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest., 101:311-320.